Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yoshihiko Taniguchi, MD"'
Autor:
Yuhei Kinehara, MD, PhD, Takayuki Shiroyama, MD, PhD, Akihiro Tamiya, MD, Motohiro Tamiya, MD, Seigo Minami, MD, PhD, Masaki Kanazu, MD, Osamu Morimura, MD, PhD, Toshie Niki, MD, PhD, Satoshi Tetsumoto, MD, PhD, Yoshihiko Taniguchi, MD, Tomoki Kuge, MD, Kazumi Nishino, MD, PhD, Izumi Nagatomo, MD, PhD, Atsushi Kumanogoh, MD, PhD, Isao Tachibana, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100586- (2023)
Introduction: Durvalumab consolidation therapy is the standard of care after concurrent chemoradiotherapy (CRT) for stage III NSCLC. Immune-related pneumonitis during durvalumab treatment is potentially fatal; however, information is lacking regardin
Externí odkaz:
https://doaj.org/article/c22883f5a74346ae94c511208d4a9489
Autor:
Tomoki Kuge, MD, Takayuki Shiroyama, MD, PhD, Akihiro Tamiya, MD, Motohiro Tamiya, MD, Masaki Kanazu, MD, Yuhei Kinehara, MD, PhD, Tsunehiro Tanaka, MD, Osamu Morimura, MD, PhD, Yoshihiko Taniguchi, MD, Toshie Niki, MD, PhD, Satoshi Tetsumoto, MD, PhD, Kazuhiko Hayashi, MD, PhD, Kazumi Nishino, MD, PhD, Izumi Nagatomo, MD, PhD, Atsushi Kumanogoh, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100505- (2023)
Introduction: Durvalumab maintenance therapy after definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III NSCLC. Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of subsequ
Externí odkaz:
https://doaj.org/article/dc6115d79b3b49f897868ff430d9099c
Autor:
Hayato Kawachi, MD, Motohiro Tamiya, MD, Yoshihiko Taniguchi, MD, Toshihide Yokoyama, MD, Shinya Yokoe, MD, Yuko Oya, MD, PhD, Mihoko Imaji, MD, Fukuko Okabe, MD, Masaki Kanazu, MD, Yoshihiko Sakata, MD, Shinya Uematsu, MD, Satoshi Tanaka, MD, Daisuke Arai, MD, PhD, Go Saito, MD, Hiroshi Kobe, MD, Eisaku Miyauchi, MD, PhD, Asuka Okada, MD, PhD, Satoshi Hara, MD, Toru Kumagai, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100355- (2022)
Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard therapy for
Externí odkaz:
https://doaj.org/article/a1964b63c30847029c4b83600c97ce97